leisure time -WSS

leisure time

author：Wikipedia 2025-09-30 22:07:57 - browse：64

Person wearing a smart watch. -- first opinion coverage from STAT — Adobe

The Apple Watch has secured a new qualification from the Food and Drug Administration that could make the smartwatch an appealing tool for medical device companies hoping to illustrate the benefits of a common heart procedure.

Last week, the Apple Watch’s Atrial Fibrillation History feature became the first digital tool qualified under the Medical Device Development Tools (MDDT) program. Released in 2022, the feature estimates a user’s A-fib burden, or how much time they spend in atrial fibrillation, which is an irregular heart rhythm that can cause shortness of breath and fatigue, and is also linked to an increased risk of stroke.

The qualification means that FDA has determined in advance that sponsors can use the feature as a secondary endpoint in clinical trials without having to do additional work. Specifically, the Apple Watch is qualified for use as a secondary endpoint in clinical trials for cardiac ablation devices, which reduce the electrical signals that cause A-fib by scarring the heart with extreme heat or cold energy. Pulsed field ablation is the latest version of the technology, using a controlled electric field to scar tissue rather than the riskier thermal energy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Police still searching for prisoner who escaped from NYC hospital

knowledge

WSS

How to use technology to prevent future drug shortages

NIH trials fail to test meaningful long Covid therapies, experts say

Drastic changes should bring profitability, startup health insurers say

STAT Summit: Ending the crisis of Black deaths in the U.S.

STAT Summit: Meghan O’Rourke on making chronic illness visible

The best solution to the drug shortages problem

entertainment

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

Duchenne breakthrough therapy leaves behind pioneering families

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

Heart attack and stroke risk calculators need revising

Wegovy trial has doctors encouraged over new possibilities

After affirmative action ruling, medical educators look to 'holistic review'

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Man killed during FBI raid in connection with threats against Biden, other officials

Medical leaders decry Supreme Court decision on affirmative action

Why failed clinical trials don’t always spell doom for a new drug

entertainment

Smaller biotechs seek to piggyback on weight loss drug boom

J&J lung cancer data amount to new salvo against AstraZeneca

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

In same hospitals, Black patients receive fewer opioids than white patients

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Roivant's CEO is a star, but biotech's black hole persists

knowledge

Wikipedia

knowledge

focus